Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Abstract

The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in the context of the current clinical standard of care.

Keywords:

• Non-small cell lung cancer
• metastatic
• advanced
• adjuvant

Disclosure statement

SA, PA, NK and AD do not have any disclosures. LH – Outside of current manuscript: research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda (all institutions, Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly, AstraZeneca (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars/podcast: Benecke, Medtalks, VJOncology (self), high5oncology, Takeda (institution); interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Mirati, Abbvie.